These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 18991873)
1. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity. Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873 [TBL] [Abstract][Full Text] [Related]
2. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles. Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277 [TBL] [Abstract][Full Text] [Related]
3. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585 [TBL] [Abstract][Full Text] [Related]
4. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219 [TBL] [Abstract][Full Text] [Related]
9. Acrylamide inhibits dopamine uptake in rat striatal synaptic vesicles. LoPachin RM; Barber DS; He D; Das S Toxicol Sci; 2006 Jan; 89(1):224-34. PubMed ID: 16207938 [TBL] [Abstract][Full Text] [Related]
10. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Easton N; Steward C; Marshall F; Fone K; Marsden C Neuropharmacology; 2007 Feb; 52(2):405-14. PubMed ID: 17020775 [TBL] [Abstract][Full Text] [Related]
11. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. Volz TJ; Hanson GR; Fleckenstein AE J Neurosci Methods; 2006 Jul; 155(1):109-15. PubMed ID: 16480775 [TBL] [Abstract][Full Text] [Related]
12. Methylphenidate modifies overflow and presynaptic compartmentalization of dopamine via an α-synuclein-dependent mechanism. Chadchankar H; Ihalainen J; Tanila H; Yavich L J Pharmacol Exp Ther; 2012 May; 341(2):484-92. PubMed ID: 22344407 [TBL] [Abstract][Full Text] [Related]
14. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Hanson GR; Sandoval V; Riddle E; Fleckenstein AE Ann N Y Acad Sci; 2004 Oct; 1025():146-50. PubMed ID: 15542712 [TBL] [Abstract][Full Text] [Related]
15. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. Brown JM; Hanson GR; Fleckenstein AE J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. Midde NM; Gomez AM; Zhu J J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010 [TBL] [Abstract][Full Text] [Related]
17. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625 [TBL] [Abstract][Full Text] [Related]
18. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. Alburges ME; Hoonakker AJ; Horner KA; Fleckenstein AE; Hanson GR J Neurochem; 2011 May; 117(3):470-8. PubMed ID: 21323925 [TBL] [Abstract][Full Text] [Related]